
AgomAb Therapeutics NV (NASDAQ:AGMB – Free Report) – Investment analysts at HC Wainwright lifted their FY2026 earnings per share estimates for AgomAb Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($1.87) for the year, up from their prior estimate of ($1.91). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.72) EPS, FY2029 earnings at ($1.77) EPS and FY2030 earnings at ($1.75) EPS.
Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. Johnson Rice reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Finally, Piper Sandler started coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.50.
Check Out Our Latest Stock Analysis on AGMB
AgomAb Therapeutics Stock Down 0.8%
AGMB stock opened at $5.92 on Wednesday. The company has a 50-day simple moving average of $9.20 and a 200 day simple moving average of $11.67. AgomAb Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $17.82.
Insider Transactions at AgomAb Therapeutics
In other news, Director David Epstein acquired 14,980 shares of the company’s stock in a transaction dated Friday, November 13th. The shares were bought at an average price of $5.92 per share, with a total value of $88,681.60. Following the purchase, the director owned 54,980 shares of the company’s stock, valued at approximately $325,481.60. This represents a 37.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Pierre Kemula acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The stock was purchased at an average price of $8.59 per share, with a total value of $85,900.00. Following the acquisition, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $85,900. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 70,980 shares of company stock valued at $549,262.
AgomAb Therapeutics Company Profile
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-? receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Read More
- Five stocks we like better than AgomAb Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
